Log in

NASDAQ:FBIO - Fortress Biotech Stock Price, Forecast & News

$1.96
+0.01 (+0.51 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$1.93
Now: $1.96
$2.06
50-Day Range
$1.25
MA: $1.71
$2.14
52-Week Range
$0.49
Now: $1.96
$2.59
Volume161,009 shs
Average Volume237,386 shs
Market Capitalization$138.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.88 million
Book Value$0.35 per share

Profitability

Net Income$-84,150,000.00
Net Margins-143.08%

Miscellaneous

Employees68
Market Cap$138.73 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.


Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) released its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $9.77 million for the quarter, compared to analyst estimates of $8.49 million. Fortress Biotech had a negative return on equity of 131.74% and a negative net margin of 143.08%. View Fortress Biotech's Earnings History.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech.

What price target have analysts set for FBIO?

3 equities research analysts have issued 12-month target prices for Fortress Biotech's shares. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's share price to reach $11.33 in the next year. This suggests a possible upside of 478.2% from the stock's current price. View Analyst Price Targets for Fortress Biotech.

What is the consensus analysts' recommendation for Fortress Biotech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:
  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019)

Has Fortress Biotech been receiving favorable news coverage?

Press coverage about FBIO stock has trended neutral on Sunday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fortress Biotech earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Fortress Biotech.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a decline in short interest in November. As of November 29th, there was short interest totalling 1,030,000 shares, a decline of 11.2% from the November 14th total of 1,160,000 shares. Based on an average trading volume of 255,600 shares, the days-to-cover ratio is currently 4.0 days. Currently, 2.1% of the shares of the company are sold short. View Fortress Biotech's Current Options Chain.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Geron (GERN), ZIOPHARM Oncology (ZIOP), Novavax (NVAX), T2 Biosystems (TTOO) and Verastem (VSTM).

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)
  • Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65)

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.58%), FNY Investment Advisers LLC (0.29%), Shikiar Asset Management Inc. (0.26%), PVG Asset Management Corp (0.11%), State Street Corp (0.11%) and Rational Advisors LLC (0.11%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.

Which institutional investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and State Street Corp. View Insider Buying and Selling for Fortress Biotech.

Which institutional investors are buying Fortress Biotech stock?

FBIO stock was acquired by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc., PVG Asset Management Corp, Rational Advisors LLC, FNY Investment Advisers LLC and Tower Research Capital LLC TRC. View Insider Buying and Selling for Fortress Biotech.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $1.96.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $138.73 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel